Trends in Conventional Heart Failure Therapy in a Real-World Multinational ATTR-CA Cohort

Background: Conventional HF treatment in transthyretin cardiac amyloidosis (ATTR-CA) resulting in restrictive cardiomyopathy is debated due to absent trial evidence in this specific sub-population of heart failure (HF) patients. Current European Society of Cardiology guidelines recommend the use of...

Full description

Bibliographic Details

Published in:	Journal of Cardiovascular Development and Disease
Main Authors:	Eva H. van der Geest, Nina Ajmone Marsan, Dorien Laenens, Philippe J. M. R. Debonnaire, Mathias Claeys, Fauto Pinto, Dulce Brito, Erwan Donal, Steven Droogmans, Nico Van de Veire, Philippe Bertrand, Takeru Nabeta, Francesca Graziani, Madelien V. Regeer
Format:	Article
Language:	English
Published:	MDPI AG 2025-10-01
Subjects:	transthyretin cardiac amyloidosis heart failure medication beta-blockers angiotensin-converting enzyme inhibitors angiotensin II receptor blockers
Online Access:	https://www.mdpi.com/2308-3425/12/10/403